Loading...
Market
Number of additional RNA silencing therapies approved by FDA in 2024?
5
Resolution / Starting Odds
None • 33%
One • 33%
Two or more • 33%
FDA official announcements and industry reports
Story
Alnylam's Vutrisiran Shows Positive Results in Phase 3 Heart Disease Study, Stock Surges 30%
Jun 24, 2024, 11:15 AM
Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, a treatment for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The late-stage study achieved statistical significance on primary and all secondary endpoints in both overall and monotherapy populations. Vutrisiran demonstrated a reduction in the risk of death and recurrent cardiovascular complications. This success likely paves the way for vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The positive results have also led to a significant increase in Alnylam's stock price, which surged by 30%.
View original story
Similar markets
ARO-DUX4 • 25%
ARO-MMP7 • 25%
Other program • 25%
No program reaches Phase 2 • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Cancer • 25%
Diabetes • 25%
Autoimmune Disease • 25%
Other • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%